Literature DB >> 21774451

Phenotype analysis of an Australian DFNA9 family with the 1109N COCH mutation.

Robert J Pauw1, Patrick L M Huygen, Gordon M Colditz, Cor W R J Cremers.   

Abstract

OBJECTIVES: We studied the clinical characteristics of an Australian family with an autosomal dominant sensorineural hearing impairment (DFNA9) caused by an I109N mutation in COCH.
METHODS: Retrospective analyses of audiometric data from 8 mutation carriers of an Australian DFNA9 family with the I109N COCH mutation were performed. Cross-sectional hearing levels related to age, age-related typical audiograms, and speech recognition scores related to age and to the level of hearing impairment were investigated. Data were compared to those obtained in previously identified DFNA9 families with P51S, V66G, G87W, G88E, I109T, and C542F COCH mutations.
RESULTS: Deterioration of hearing in the I109N mutation carriers started before the age of 40 years. The audiometric characteristics of the I109N mutation carriers are essentially similar to those previously established in I109T mutation carriers and, to a lesser extent, in P51S, G87W, and G88E mutation carriers.
CONCLUSIONS: The phenotype associated with the I109N COCH mutation is largely similar to that associated with the I109T, P51S, G87W, and G88E mutation carriers. However, subtle differences seem to exist in terms of age of onset and rate of progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21774451     DOI: 10.1177/000348941112000612

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  7 in total

1.  Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia.

Authors:  Lang Li; Tammy Sajdyk; Ellen M L Smith; Chien Wei Chang; Claire Li; Richard H Ho; Raymond Hutchinson; Elizabeth Wells; Jodi L Skiles; Naomi Winick; Paul L Martin; Jamie L Renbarger
Journal:  Clin Pharmacol Ther       Date:  2019-01-21       Impact factor: 6.875

Review 2.  Progress and prospects in human genetic research into age-related hearing impairment.

Authors:  Yasue Uchida; Saiko Sugiura; Michihiko Sone; Hiromi Ueda; Tsutomu Nakashima
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

3.  Different Phenotypes of the Two Chinese Probands with the Same c.889G>A (p.C162Y) Mutation in COCH Gene Verify Different Mechanisms Underlying Autosomal Dominant Nonsyndromic Deafness 9.

Authors:  Qi Wang; Peipei Fei; Hongbo Gu; Yanmei Zhang; Xiaomei Ke; Yuhe Liu
Journal:  PLoS One       Date:  2017-01-18       Impact factor: 3.240

4.  Novel EYA4 variant in Slovak family with late onset autosomal dominant hearing loss: a case report.

Authors:  Lukas Varga; Daniel Danis; Martina Skopkova; Ivica Masindova; Zuzana Slobodova; Lucia Demesova; Milan Profant; Daniela Gasperikova
Journal:  BMC Med Genet       Date:  2019-05-17       Impact factor: 2.103

Review 5.  Genotype-Phenotype Correlations of Pathogenic COCH Variants in DFNA9: A HuGE Systematic Review and Audiometric Meta-Analysis.

Authors:  Sybren M M Robijn; Jeroen J Smits; Kadriye Sezer; Patrick L M Huygen; Andy J Beynon; Erwin van Wijk; Hannie Kremer; Erik de Vrieze; Cornelis P Lanting; Ronald J E Pennings
Journal:  Biomolecules       Date:  2022-01-27

6.  Usher syndrome type IV: clinically and molecularly confirmed by novel ARSG variants.

Authors:  Hannie Kremer; Cornelis P Lanting; Markus Damme; Hedwig M Velde; Janine Reurink; Sebastian Held; Catherina H Z Li; Suzanne Yzer; Jaap Oostrik; Jack Weeda; Lonneke Haer-Wigman; Helger G Yntema; Susanne Roosing; Laurenz Pauleikhoff; Clemens Lange; Laura Whelan; Adrian Dockery; Julia Zhu; David J Keegan; G Jane Farrar; Ronald J E Pennings
Journal:  Hum Genet       Date:  2022-02-28       Impact factor: 5.881

7.  Does Otovestibular Loss in the Autosomal Dominant Disorder DFNA9 Have an Impact of on Cognition? A Systematic Review.

Authors:  Jonas De Belder; Stijn Matthysen; Annes J Claes; Griet Mertens; Paul Van de Heyning; Vincent Van Rompaey
Journal:  Front Neurosci       Date:  2018-01-09       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.